



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 3/16/2017
LAST REVIEW DATE: 5/20/2021
LAST CRITERIA REVISION DATE: 5/20/2021
ARCHIVE DATE:

RUBRACA™ (rucaparib camsylate)

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the [request form](#) in its entirety with the chart notes as documentation. **All requested data must be provided.** Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 3/16/2017
LAST REVIEW DATE: 5/20/2021
LAST CRITERIA REVISION DATE: 5/20/2021
ARCHIVE DATE:

RUBRACA™ (rucaparib camsylate)

Criteria:

- **Criteria for initial therapy:** Rubraca (rucaparib camsylate) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with an Oncologist
 2. Individual is 18 years of age or older
 3. A confirmed diagnosis of **ONE** of the following:
 - a. Epithelial ovarian, fallopian tube, or primary peritoneal cancer with a deleterious *BRCA* mutation (germline and/or somatic) who have been treated with two or more lines of chemotherapy
 - b. Epithelial ovarian, fallopian tube, or primary peritoneal cancer who have completed two or more lines of platinum-based therapy and are in a complete or partial response
 - c. Deleterious *BRCA* mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy and are to receive concomitant gonadotropin-releasing hormone (GnRH) analog or had a prior bilateral orchiectomy
 - d. Other request for a specific oncologic direct treatment use that is found and listed in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1 and 2A
 4. **ALL** of the following baseline tests have been completed before initiation of treatment:
 - a. Documentation of deleterious *BRCA* gene mutation, either inherited (germline) or acquired (somatic), confirmed by an FDA-approved test is required for prostate cancer and for ovarian cancer after 2 or more chemotherapies
 - b. Negative pregnancy test in a woman of reproductive potential
 - c. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
 5. Individual does not have moderate to severe hepatic impairment (total bilirubin greater than 1.5 times the upper limit of normal)
 6. Individual does not have a creatinine clearance of less than 30 mL/min or on dialysis

Initial approval duration: 6 months

- **Criteria for continuation of coverage (renewal request):** Rubraca (rucaparib camsylate) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with an Oncologist



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 3/16/2017
LAST REVIEW DATE: 5/20/2021
LAST CRITERIA REVISION DATE: 5/20/2021
ARCHIVE DATE:

RUBRACA™ (rucaparib camsylate)

2. Individual's condition responded while on therapy
 - a. Response is defined as:
 - i. No evidence of disease progression
 - ii. No evidence individual has developed any significant unacceptable adverse drug reactions that may exclude continued use
3. Individual has been adherent with the medication
4. Individual has not developed any significant adverse drug effects that may exclude continued use
 - a. Significant adverse effect such as:
 - i. Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML)
5. Individual does not have moderate to severe hepatic impairment (total bilirubin greater than 1.5 times the upper limit of normal)
6. Individual does not have a creatinine clearance of less than 30 mL/min or on dialysis
7. There are no significant interacting drugs

Renewal duration: 12 months

- Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:
1. **Off-Label Use of a Non-Cancer Medications**
 2. **Off-Label Use of a Cancer Medication for the Treatment of Cancer without a Specific Coverage Guideline**

Description:

Rubraca (rucaparib camsylate) is indicated as monotherapy for the treatment of individuals with deleterious *BRCA* mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Selection of individuals for therapy is based on an FDA-approved diagnostic test. Rubraca is also indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Rubraca (rucaparib camsylate) is indicated for the treatment of adult patients with a deleterious *BRCA* mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The prostate cancer indication was approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 3/16/2017
LAST REVIEW DATE: 5/20/2021
LAST CRITERIA REVISION DATE: 5/20/2021
ARCHIVE DATE:

RUBRACA™ (rucaparib camsylate)

Rucaparib is an inhibitor of the mammalian polyadenosine 5'-diphosphoribose polymerase (PARP) enzymes, including PARP-1, PARP-2, and PARP-3 that play a role in deoxyribonucleic acid (DNA) transcription, cell cycle regulation, and DNA repair. Inhibition of PARP enzymatic activity results in increased formation of PARP-DNA complexes that cause DNA damage, apoptosis, and cell death, especially in tumor cell lines with deficiencies in *BRCA 1/2*.

Another PARP enzyme inhibitor, Lynparza (olaparib), is also indicated as monotherapy in individuals with deleterious or suspected deleterious germline *BRCA* mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

Resources:

Rubraca (rucaparib) product information, revised by Clovis Oncology, Inc. 10-2020. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed on March 19, 2021.

Moore KM, Markham MJ. Management of ovarian cancer associated with *BRCA* and other genetic mutations. In: UpToDate, Goff B, Dizon DS, Vora SR (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Accessed on March 19, 2021.

Coleman RL, Sabbatini P. Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum sensitive disease. In: UpToDate, Goff B, Dizon DS, Vora SR (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Accessed on March 19, 2021.

Dawson NA. Overview of the treatment of disseminated castration-sensitive prostate cancer. In: UpToDate, Vogelzang N, Lee WR, Richie JR, Savarese DMF (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Accessed on March 15, 2021.

Dawson NA. Overview of the treatment of castration-resistant prostate cancer (CRPC). In: UpToDate, Vogelzang N, Lee WR, Richie JR, Savarese DMF (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Accessed on March 15, 2021.

Lee RJ, Smith MR. Initial systemic therapy for castration-sensitive prostate cancer. In: UpToDate, Vogelzang N, Lee WR, Richie JR, Savarese DMF (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Accessed on March 15, 2021.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 2.2021 – Updated February 26, 2021. Available at <https://www.nccn.org>. Accessed on March 19, 2021.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate Cancer Version 2.2021 – Updated February 17, 2021. Available at <https://www.nccn.org>. Accessed on March 15, 2021.



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 3/16/2017
LAST REVIEW DATE: 5/20/2021
LAST CRITERIA REVISION DATE: 5/20/2021
ARCHIVE DATE:

RUBRACA™ (rucaparib camsylate)

National Comprehensive Cancer Network (NCCN) Compendium: Rubraca. National Comprehensive Cancer Network (NCCN). NCCN Drugs & Biologics Compendium. 2021(c); Available at: <http://www.nccn.org>. Accessed on March 19, 2021.

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.
